research use only
Cat.No.S9794
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Phospholipase (e.g. PLA) Inhibitors | Varespladib (LY315920) U-73122 GW4869 Tanshinone I Darapladib (SB-480848) Quinacrine 2HCl CAY10593 (VU0155069) m-3M3FBS Trigonelline ST 271 |
|
In vitro |
Water : 100 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 2846.46 | Formula | C131H229N39O31 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 20449-79-0, 37231-28-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | MLT, Forapin, Forapine | Smiles | CCC(C)C(NC(=O)CN)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(CC2=C[NH]C3=C2C=CC=C3)C(=O)C(=O)C(NC(=O)C(CCCCN)NNC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O)C(C)CC | ||
| Targets/IC50/Ki |
PLA2
|
|---|---|
| In vitro |
In vitro studies using TNF-α/IFN-γ-stimulated human keratinocytes shows that melittin inhibits the increased expression of chemokines, such as CCL17 and CCL22, and pro-inflammatory cytokines, including IL-1β, IL-6 and IFN-γ, through the blockade of the NF‐κB and STAT signalling pathways. |
| In vivo |
Melittin exhibits potent anti-atopic activities, shown by decreased Atopic dermatitis (AD)-like skin lesions, induced by DNCB in mice. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05617833 | Recruiting | Intraventricular Hemorrhage of Prematurity |
Johns Hopkins University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
April 15 2024 | Phase 1 |
| NCT05827575 | Recruiting | Functional Dyspepsia|Sleep Disturbances |
Second Affiliated Hospital of Xi''an Jiaotong University |
March 30 2022 | Not Applicable |
| NCT02537431 | Completed | X-linked Hypophosphatemia |
Kyowa Kirin Inc.|Kyowa Kirin Co. Ltd. |
December 23 2015 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.